Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
Facebook
Site search
Search
Menu
Subscribe
Home
Contact Us
Terms of Use
Privacy Policy
Home Delivery
Subscribe
Submission Forms
Place an Ad
Weather
News
Sports
Entertainment
Calendar
Obituaries
Classifieds
Place an ad
e-Edition
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
GeneDx Holdings Corp. - Class A Common Stock
(NQ:
WGS
)
76.35
-1.65 (-2.12%)
Streaming Delayed Price
Updated: 4:00 PM EST, Feb 14, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about GeneDx Holdings Corp. - Class A Common Stock
< Previous
1
2
3
Next >
GeneDx Announces ultraRapid Whole Genome Sequencing, Delivering Actionable Results in as soon as 48 Hours to Inform Care for Critically Ill NICU and PICU Patients
February 13, 2025
From
GeneDx
Via
Business Wire
GeneDx to Participate in 45th Annual TD Cowen Health Care Conference
February 12, 2025
From
GeneDx
Via
Business Wire
GeneDx Integrates with Epic, Enabling Broad Adoption of Genome and Exome Sequencing for Health Systems to Inform Patient Diagnosis and Accelerate Treatment
February 10, 2025
From
GeneDx
Via
Business Wire
GeneDx to Report Fourth Quarter and Full Year 2024 Financial Results on Tuesday, February 18, 2025
January 28, 2025
From
GeneDx
Via
Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
January 17, 2025
From
GeneDx
Via
Business Wire
GeneDx Announces Preliminary 2024 Financial Results
January 13, 2025
From
GeneDx
Via
Business Wire
GeneDx Introduces New Telehealth Pathway to Expand Access to Exome Testing for Parents Seeking Answers
January 09, 2025
From
GeneDx
Via
Business Wire
GeneDx Continues its Leadership in Genomics Research, Refining Gene-Disease Relationships and Impacting Results of >22,000 Patients
January 08, 2025
From
GeneDx
Via
Business Wire
GeneDx Strengthens Executive Leadership Team with Bryan Dechairo Named Chief Operating Officer
January 02, 2025
From
GeneDx
Via
Business Wire
GeneDx to Present at the 43rd Annual J.P. Morgan Healthcare Conference
December 16, 2024
From
GeneDx
Via
Business Wire
GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners
December 05, 2024
From
GeneDx
Via
Business Wire
GeneDx to Participate in Upcoming Investor Conference
November 22, 2024
From
GeneDx
Via
Business Wire
GeneDx Fuels Rare Disease Drug Discovery with Launch of GeneDx Discover
November 19, 2024
From
GeneDx
Via
Business Wire
GeneDx Announces Heidi Chen as Chief Legal Officer and Corporate Secretary
November 18, 2024
From
GeneDx
Via
Business Wire
New GeneDx Study Reveals Racial Disparities in Genetic Diagnosis Due to Systemic Barriers, Not Diagnostic Yields
November 07, 2024
From
GeneDx
Via
Business Wire
GeneDx to Highlight Key Research Findings at American Society of Human Genetics (ASHG) Annual Meeting
November 04, 2024
From
GeneDx
Via
Business Wire
GeneDx Reports Third Quarter 2024 Financial Results and Business Highlights
October 29, 2024
From
GeneDx
Via
Business Wire
Groundbreaking GUARDIAN Study Shows Benefits of Adding Genome Sequencing to Newborn Screening; Augments and Improves Standard Newborn Screening
October 24, 2024
From
GeneDx
Via
Business Wire
GeneDx to Showcase Data from Largest Genomic Newborn Screening Cohort of 14,000 Newborns
October 08, 2024
From
GeneDx
Via
Business Wire
GeneDx to Report Third Quarter 2024 Financial Results on Tuesday, October 29, 2024
October 03, 2024
From
GeneDx
Via
Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
September 27, 2024
From
GeneDx
Via
Business Wire
GeneDx to Participate in Fall Investor Conferences
August 12, 2024
From
GeneDx
Via
Business Wire
GeneDx Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
August 09, 2024
From
GeneDx
Via
Business Wire
GeneDx Announces Whole Genome Sequencing (WGS) Product Enhancements to Accelerate Diagnoses for More Patients
July 30, 2024
From
GeneDx
Via
Business Wire
GeneDx Reports Second Quarter 2024 Financial Results and Business Highlights
July 30, 2024
From
GeneDx
Via
Business Wire
GeneDx to Report Second Quarter 2024 Financial Results on Tuesday, July 30, 2024
July 11, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Collaboration with Epic Aura to Expand Access to Rapid Whole Genome Sequencing (rWGS) Services to Inform Diagnosis in Affected Pediatric and Neonatal Patients
June 10, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Announces Patient Access Program to Expand Access to Exome Testing for Pediatric Epilepsy Patients
June 05, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx to Participate in Upcoming Investor Conferences
May 22, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
GeneDx Reports First Quarter 2024 Financial Results and Business Highlights
April 29, 2024
From
GeneDx Holdings Corp.
Via
GlobeNewswire
< Previous
1
2
3
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.